Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis (COMP-RMS)

Nantes University Hospital (NUH)

Status: Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Treatments: Other: Non interventional study

Study type: Observational

Funder types: Other

Identifiers

NCT03302442

RC16_0471

Details and patient eligibility

About

The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from French Observatory of Multiple Sclerosis (French MS cohort )

Enrollment: 3,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• RRMS Patients with an EDSS score ranging between 0 and 5.5, who initiated either DMF or Teriflunomide before 1/01/2016 and with an available MRI scan and EDSS assessment respectively within 12 and 6 months before treatment initiation Patients who had consent to OFSEP registry Naive patient or treated with prior first line treatment : interferon, glatiramer acetate

Exclusion criteria

• Patient with progressive multiple sclerosis
• Patients with prior second line Patient with no MRI or EDSS score within the year before DMF or Teriflunomide initiation.